Live Chat ×
Skip to main content

From MDS to AML: What Every MDS Patient Needs to Know

Over time, about one-third of all MDS cases evolve to become AML. The risk of developing AML depends largely on the MDS subtype.

During this program, Dr. Ross Levine from Memorial Sloan Kettering Cancer Center explains the relationship between MDS and AML and how the progression occurs. He  describes how each disease is diagnosed and the symptoms you may experience. Dr. Levine concludes with the latest and emerging treatment options and practical tips for taking charge of your care. 

By the end of this program, you will understand:

  • The prognosis from MDS to AML
  • Genetic mutations associated with MDS and AML
  • Questions you should ask your healthcare team
This webinar is brought to you the generous support of Celgene, Takeda and Agios as well as in collaboration with the Leukemia and Lymphoma Society